Evidence map›Paper›PMID 30061611›Full record

ArticleScientific reports2018

Fc-apelin fusion protein attenuates lipopolysaccharide-induced liver injury in mice.

Huifen Zhou, Rongze Yang, Weimin Wang, Feng Xu, Yue Xi, Robert A Brown, Hong Zhang, Lin Shi, Dalong Zhu, Da-Wei Gong

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Huifen ZhouDepartment of Pathology, Hubei University of Science and Technology, Xianning, Hubei, 437100, China.
Rongze YangDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA.
Weimin WangDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA.
Feng XuDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA.
Yue XiDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA.
Robert A BrownDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA.
Hong ZhangDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA.
Lin ShiDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA.
Dalong ZhuNanjing University School of Medicine, Nanjing, China.
Da-Wei GongDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA. dgong@medicine.umaryland.edu.
University of Maryland, Baltimore · USNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apelin is a peptide hormone with anti-oxidative and anti-inflammatory activities and is proposed to be a potential therapeutic for many disease conditions, including sepsis. However, short in vivo half-life of the apelin peptide would limit its potential clinical applications. This study aims to investigate the effects of Fc-apelin, a novel long-acting apelin fusion protein, on lipopolysaccharide (LPS)-induced liver injury. Liver injury was induced by systemic injection of LPS in mice. Hepatoprotective activities of Fc-apelin against inflammation were evaluated in LPS mice and/or hepatoma Huh-7 cells with respect to serum ALT, apoptosis, oxidative stress, macrophage infiltration and gene expression. We found that LPS induced systemic inflammation and liver damage. Co-administration of Fc-apelin significantly attenuated serum ALT elevation, diminished LPS-induced apoptosis and ROS production in the liver and in Huh-7 cells, mitigated hepatic macrophage infiltration, and reduced TNFα and IL-6 gene expression. Collectively, Fc-apelin fusion protein exerts protective effects against LPS-induced liver damage and may serve as a potential therapeutic for endotoxin-induced liver injury.

Indexed as

Alanine TransaminaseAnimalsApelinApoptosisCell Line, TumorFemaleHumansInterleukin-6LipopolysaccharidesLiverMacrophagesMiceMice, Inbred C57BLProtective AgentsReactive Oxygen SpeciesReceptors, FcAlanine TransaminaseApelinInterleukin-6LipopolysaccharidesProtective AgentsReactive Oxygen SpeciesReceptors, FcRecombinant Fusion ProteinsRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID30061611
PMCPMC6065397
OpenAlexW2883301596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.